{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=120",
    "query": {
      "condition": "Advanced Malignancy",
      "page": 120
    },
    "page_size": 10
  },
  "pagination": {
    "page": 120,
    "page_size": 10,
    "total_count": 9821,
    "total_pages": 983,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=121&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=119&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T21:16:44.498Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03797326",
      "title": "Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Triple Negative Breast Cancer",
        "Ovarian Cancer",
        "Gastric Cancer",
        "Colorectal Cancer",
        "Glioblastoma",
        "Biliary Tract Cancers",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 611,
      "start_date": "2019-02-12",
      "completion_date": "2024-10-28",
      "has_results": true,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-11-15T21:16:44.498Z",
      "location_count": 14,
      "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 11 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03797326"
    },
    {
      "nct_id": "NCT06874335",
      "title": "A Phase 1 Study of BHV-1530 in Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "BHV-1530",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biohaven Therapeutics Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2025-03-20",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-11-15T21:16:44.498Z",
      "location_count": 17,
      "location_summary": "Newport Beach, California • Denver, Colorado • Lake Mary, Florida + 14 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06874335"
    },
    {
      "nct_id": "NCT00004063",
      "title": "Cisplatin, Gemcitabine, Interferon Alfa, and Hyperthermia in Treating Patients With Advanced Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "recombinant interferon alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "hyperthermia treatment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "1999-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2009-04-30",
      "last_synced_at": "2026-11-15T21:16:44.498Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004063"
    },
    {
      "nct_id": "NCT06790693",
      "title": "A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Inavolisib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "CDK4/6i",
          "type": "DRUG"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 450,
      "start_date": "2025-04-09",
      "completion_date": "2032-02-01",
      "has_results": false,
      "last_update_posted_date": "2026-11-04",
      "last_synced_at": "2026-11-15T21:16:44.498Z",
      "location_count": 62,
      "location_summary": "Goodyear, Arizona • Phoenix, Arizona • Burbank, California + 50 more",
      "locations": [
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06790693"
    },
    {
      "nct_id": "NCT05975593",
      "title": "MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Locally Advanced Cervical Carcinoma",
        "Locally Advanced Cervical Cancer",
        "Locally Advanced Pancreas Cancer",
        "Locally Advanced Pancreatic Carcinoma",
        "Locally Advanced Pancreatic Cancer",
        "Cervical Cancer",
        "Pancreas Cancer",
        "Pancreatic Cancer",
        "Cancer of the Cervix",
        "Cancer of the Pancreas"
      ],
      "interventions": [
        {
          "name": "Tumor collection via biopsy",
          "type": "OTHER"
        },
        {
          "name": "Blood collection",
          "type": "OTHER"
        },
        {
          "name": "Diffusion basis spectrum imaging (DBSI) magnetic resonance imaging (MRI)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DEVICE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2024-01-11",
      "completion_date": "2032-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-11-15T21:16:44.498Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05975593"
    },
    {
      "nct_id": "NCT01292655",
      "title": "Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "BMS-906024",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 94,
      "start_date": "2011-03-03",
      "completion_date": "2017-06-22",
      "has_results": false,
      "last_update_posted_date": "2020-01-27",
      "last_synced_at": "2026-11-15T21:16:44.498Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Atlanta, Georgia • Detroit, Michigan + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Jackson",
          "state": "Mississippi"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01292655"
    },
    {
      "nct_id": "NCT06750185",
      "title": "Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "BNT317 DL1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT317 DL2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT317 DL3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT317 DL4",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT317 DL5",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT317 DL6",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT317 selected DLA",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BNT317 selected DLB",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SoC chemotherapy 1",
          "type": "DRUG"
        },
        {
          "name": "SoC chemotherapy 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 248,
      "start_date": "2025-01-13",
      "completion_date": "2031-04",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-11-15T21:16:44.498Z",
      "location_count": 7,
      "location_summary": "Louisville, Kentucky • Grand Rapids, Michigan • Huntersville, North Carolina + 4 more",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Huntersville",
          "state": "North Carolina"
        },
        {
          "city": "East Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06750185"
    },
    {
      "nct_id": "NCT03489343",
      "title": "Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Cancer",
        "Solid Tumor",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Sym023",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Symphogen A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2018-05-24",
      "completion_date": "2020-06-03",
      "has_results": true,
      "last_update_posted_date": "2021-10-12",
      "last_synced_at": "2026-11-15T21:16:44.498Z",
      "location_count": 3,
      "location_summary": "Grand Rapids, Michigan • Houston, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03489343"
    },
    {
      "nct_id": "NCT01379287",
      "title": "Dose-Escalation Safety and Pharmacokinetic Study of Iso-Fludelone in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Iso-Fludelone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2011-06-20",
      "completion_date": "2023-01-31",
      "has_results": false,
      "last_update_posted_date": "2023-02-02",
      "last_synced_at": "2026-11-15T21:16:44.498Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01379287"
    },
    {
      "nct_id": "NCT06630247",
      "title": "A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Cancers",
        "Solid Tumor Cancer",
        "Solid Tumor Malignancy",
        "Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)",
        "Metastatic Solid Tumor",
        "Locally Advanced Solid Tumor",
        "Urothelial Cancer of Renal Pelvis"
      ],
      "interventions": [
        {
          "name": "XL495",
          "type": "DRUG"
        },
        {
          "name": "ADC cytotoxic agents",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Exelixis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2024-10-17",
      "completion_date": "2025-05-07",
      "has_results": false,
      "last_update_posted_date": "2025-06-25",
      "last_synced_at": "2026-11-15T21:16:44.498Z",
      "location_count": 10,
      "location_summary": "Denver, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 6 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jefferson",
          "state": "Louisiana"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06630247"
    }
  ]
}